CORT Shares Plunge: FDA Warning on Relacorilant Submission

Company Overview & Latest Setback

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage biotechnology company focused on drugs that modulate the effects of cortisol. Its flagship product Korlym (mifepristone) is approved to treat Cushing’s syndrome, and the company has been developing relacorilant, a next-generation cortisol modulator, for multiple indications (www.biospace.com) (ir.corcept.com). In late 2025, Corcept submitted relacorilant for FDA approval in patients with hypertension secondary to endogenous Cushing’s syndrome. This submission met a harsh regulatory response: on December 30, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve relacorilant without additional efficacy evidence (www.biospace.com) (pharmaphorum.com). Corcept’s CEO expressed shock at the rejection – stating the company was “surprised and disappointed” by the outcome (www.biospace.com) – even as the CRL revealed that prior to filing, the FDA had repeatedly warned Corcept about “the adequacy of the clinical development program” and advised that the application would face “significant review issues” if submitted (www.fiercebiotech.com) (www.fiercebiotech.com). News that management proceeded despite these explicit FDA warnings caused CORT shares to plunge. In fact, a corrected CRL published on January 28, 2026 showed the FDA had cautioned Corcept “on several occasions” not to file the relacorilant NDA, triggering a 16% stock drop the next day (wsau.com). The share price tumbled from about $44 to the high-$30s after this revelation (www.fiercebiotech.com).

This late-January 2026 plunge compounds an already volatile period for Corcept. Just a year earlier (January 2024), CORT shares saw a steep one-day decline after the company lost a key patent dispute with Teva over Korlym, clearing a path for generic competition (apnews.com). Nonetheless, throughout 2024 and 2025 the stock had rallied on strong financial results and optimism around relacorilant. By the time of the FDA’s CRL-related disclosure in early 2026, Corcept’s market capitalization had swelled to roughly $4–5 billion, reflecting high expectations for growth. The FDA’s stinging rebuke of relacorilant’s data – and management’s credibility – now raises critical questions for investors about the company’s outlook, from its drug portfolio and pipeline prospects to its financial stability and valuation. Below we examine Corcept’s fundamentals and risks in detail, drawing on official filings and credible sources.

Dividend Policy & Shareholder Returns

Corcept does not pay any dividend and has never declared a cash dividend on its common stock (www.sec.gov) (www.sec.gov). The company’s policy has been to reinvest profits into R&D and growth, and management has explicitly stated they do not anticipate paying cash dividends for the foreseeable future (www.sec.gov). Consequently, Corcept’s dividend yield is 0.00%, and income-oriented investors receive no direct cash returns from the stock (www.macrotrends.net). Instead, Corcept has occasionally returned capital to shareholders via stock buybacks. Notably, in 2023 the company initiated a significant share repurchase: an April 2023 tender offer in which Corcept spent $154.5 million to buy back its own stock (www.biospace.com). This one-time tender represented a substantial return of capital (around 7% of the company’s market value at the time) and reduced the share count, effectively “returning” value to shareholders through share price support. Such buybacks can boost earnings per share and signal management’s confidence, but they also absorb cash that could otherwise fund pipeline development. Aside from this tender-driven buyback, Corcept has not announced regular repurchase programs, so future shareholder returns will likely hinge on stock price appreciation rather than dividends.

Dividend metrics like FFO/AFFO are not applicable here, as those are used for REITs or cash-flowing asset plays. Corcept is a biopharmaceutical company whose value is tied to drug revenues and R&D, not stable asset yields. Thus, investors focus on sales and earnings growth rather than funds-from-operations. With no dividend obligations, Corcept retains all operating cash flow for internal uses – a necessary stance given its ongoing clinical programs and the potential need to invest in additional trials post-relacorilant setback.

Financial Position: Leverage, Liquidity & Coverage

Corcept boasts a solid balance sheet with no long-term debt. The company carries zero interest-bearing debt, meaning it has no leverage and no debt maturities to worry about. Corcept’s liabilities consist mostly of routine payables and accrued expenses, with no outstanding loans or bonds reported in its SEC filings (www.sec.gov) (www.sec.gov). As a result, interest coverage is a non-issue – with no interest expense, Corcept’s operating earnings fully accrue to equity. This conservative capital structure greatly reduces financial risk. It also gives Corcept flexibility to weather setbacks: unlike many biotech peers, Corcept need not raise cash at inopportune times to service debt.

Meanwhile, Corcept has built a healthy cash reserve from its profitable Korlym franchise. As of year-end 2023, the company held $425.4 million in cash and short-term investments (www.biospace.com). One year later, by December 31, 2024, Corcept’s cash and investments had grown further to $603.2 million (ir.corcept.com) – an increase reflecting robust cash generation from operations. This liquidity provides a substantial cushion for R&D funding and any strategic needs. Even after funding its pipeline and a sizable stock buyback in 2023, Corcept’s cash position remains strong. In fact, the company’s cash on hand is equivalent to roughly 9–10% of its market cap (as of early 2026), underscoring a net cash balance sheet. Practically, this means Corcept has ample capacity to finance new clinical trials (such as any additional studies the FDA might require for relacorilant) or to acquire complementary assets, without needing to assume debt or immediately dilute shareholders.

Notably, Corcept’s existing operations are cash-generative: in 2024, the company earned $141.2 million in net income (ir.corcept.com), and its operating cash flow comfortably exceeded capital expenditures (since Corcept’s business is not asset-intensive). With no interest or principal repayments due, nearly all operating cash can be reinvested or held. Summing up, Corcept’s balance sheet strength and liquidity position it well to absorb near-term challenges. The absence of leverage eliminates default risk and interest burden, though it also means equity holders bear all the risk/reward of the company’s investments in new drugs.

Recent Performance & Valuation

Operationally, Corcept has delivered strong growth in its core business. Revenues are driven almost entirely by sales of Korlym in the U.S. Cushing’s syndrome market, and those sales have climbed steadily. In 2023, Corcept’s revenue reached $482.4 million, a 20% increase over the prior year (www.biospace.com). Growth accelerated in 2024, with full-year revenue surging 40% to $675.0 million (ir.corcept.com) as the company expanded its reach in treating hypercortisolism. This top-line momentum, combined with controlled expenses, has yielded consistent profitability. Corcept reported $106.1 million in net income for 2023 (up from $101.4M in 2022) (www.biospace.com), and earnings jumped further to $141.2 million in 2024 (ir.corcept.com). Diluted earnings per share for 2023 were approximately $0.94 (www.biospace.com), rising to roughly $1.34 for 2024 (based on the higher net income and a reduced share count post-buyback). This profitable growth is impressive for a mid-cap biotech and reflects both increasing patient uptake of Korlym and operational leverage.

Market expectations had been high. Going into 2025, Corcept’s management issued revenue guidance of $900–$950 million for the year (ir.corcept.com) – implying another ~35% annual growth. This outlook, which assumed continued expansion of Korlym and perhaps initial contributions from relacorilant by late 2025, buoyed the stock. Prior to the FDA setback, investors were pricing CORT shares at a premium valuation. At around $39–$44 per share (the trading range just before and after the CRL news), Corcept’s price-to-earnings ratio works out to roughly 40–45× trailing EPS. In other words, the stock was trading at ~40 times its 2023 earnings of $0.94 per share (www.biospace.com) – a rich multiple that anticipated significant growth and pipeline success. On a price-to-sales basis, the stock was about 6× 2024 revenues, or closer to ~4.5× using the optimistic 2025 sales guidance. Such multiples are above the broader market average and even many pharma peers, indicating that Corcept’s valuation embedded substantial future upside from its pipeline (relacorilant in Cushing’s and oncology, plus other candidates) and confidence in the durability of Korlym’s cash flows.

It’s important to note that standard REIT valuation metrics like P/FFO are not relevant here – Corcept is valued on biotech metrics (P/E, EV/EBITDA, and price/sales). Compared to other specialty biopharma companies, Corcept’s valuation had been on the higher side due to its rare combination of profitability and growth. For instance, many mid-sized biotechs are unprofitable (so P/E is not meaningful) or trade at 2–4× sales; Corcept’s premium reflected its unique position of funding its own development with internally generated earnings. However, the relacorilant CRL has likely reset these expectations downward. The stock’s pullback to the high-$30s suggests some multiple compression as investors reassess future growth. If Korlym’s trajectory slows (due to competition or saturation) and relacorilant is delayed or in jeopardy, Corcept’s earnings growth could stall, making that 40× P/E look expensive. In sum, the company’s valuation is highly contingent on pipeline progress: continued premium pricing of CORT shares will require clarity on how/if relacorilant can reach the market and contribute meaningfully to earnings.

Key Risks

1. Generic Competition for Korlym: Corcept’s reliance on Korlym (mifepristone) – its sole marketed product – is a double-edged sword. The company faces looming generic competition for Korlym, which could drastically erode revenue. Korlym’s composition-of-matter patent has expired, and generic drugmaker Teva won a patent challenge in late 2023, invalidating certain method-of-use patents and obtaining FDA approval to market a generic mifepristone (apnews.com) (www.sec.gov). Although Corcept is appealing some decisions, the reality is that a generic version of Korlym can launch (Teva has had the legal ability to market its generic since August 2020 (www.sec.gov)). To date, Korlym sales have continued to grow – suggesting limited generic erosion so far – but this could change quickly. The company itself warns that if a generic enters, Korlym sales could decline “rapidly and significantly,” materially harming revenue and results (www.sec.gov). The timing and magnitude of generic impact is an urgent uncertainty: will Teva (or others) aggressively launch, and will payers force switches to cheaper generics? If Korlym’s ~$675M in annual revenue even partially shifts to a generic, Corcept’s cash flow and profitability would drop, potentially limiting funds for R&D and lowering the stock’s fair value. This concentration risk – heavy dependence on one product nearing the end of its exclusivity – is the foremost risk to Corcept’s business.

2. Regulatory and Pipeline Risk: The recent FDA outcome underscores the risks inherent in Corcept’s pipeline. Relacorilant’s failure to secure approval is a significant setback. Despite a Phase 3 trial (GRACE) that nominally met its primary endpoint, the FDA found the totality of evidence insufficient for approval (www.biospace.com). In fact, the FDA’s CRL cited that the main trial “failed to show relacorilant worked better than placebo” with “virtually no difference between the drug and placebo” on the primary outcome (wsau.com). Additionally, safety concerns emerged – four patients in trials developed probable drug-induced liver injury, including one with liver enzymes >50× the upper limit of normal (wsau.com). These efficacy and safety issues raise doubts about relacorilant’s approvability without new studies. Corcept has one year to respond to the CRL with additional evidence or analyses, but conducting new trials (for efficacy or safety) would be costly and time-consuming. There is a risk that relacorilant for Cushing’s may be significantly delayed or never approved. Beyond relacorilant, Corcept’s pipeline includes trials of relacorilant in oncology (e.g. an NDA in platinum-resistant ovarian cancer is under FDA review with a PDUFA date of July 11, 2026 (www.biospace.com)) and other cortisol modulators like miricorilant (for NASH) and dazucorilant (for ALS). All these R&D programs carry typical clinical development risks: trial failures, regulatory rejections, or unforeseen side effects could derail them. Corcept’s future growth is predicated on pipeline success, so any further trial disappointments would have a magnified impact now that one lead program has stumbled.

3. Competitive Landscape: Even aside from generic Korlym, the Cushing’s syndrome treatment landscape is becoming more competitive. Several alternative medications to treat hypercortisolism have emerged. Notably, Recordati’s Isturisa (osilodrostat) and Xeris Biopharma’s Recorlev (levoketoconazole) were approved in recent years to treat Cushing’s syndrome by reducing cortisol production. Physicians now have multiple pharmacological choices – Korlym is no longer the only game in town. Corcept acknowledges that some doctors prefer other therapies or off-label generics (www.sec.gov) (www.sec.gov). Increased competition could limit Corcept’s ability to continue expanding Korlym sales or maintain pricing power. In the cancer arena, relacorilant (if eventually approved for ovarian cancer) would also face competition from established cancer therapies and needs to demonstrate clear additive benefit. Broadly, competitive pressure could slow Corcept’s revenue growth regardless of generics. The company’s ambitious revenue targets (e.g. projecting $900M+ in 2025) presume strong physician uptake, which might be optimistic if competitors capture more share or if payers impose step-edits favoring cheaper alternatives.

4. Legal and Reputational Risks: The FDA’s disclosure has also exposed Corcept to potential shareholder litigation. The discrepancy between the FDA’s repeated warnings and management’s public optimism (“on track for approval by end of 2025” and “strong efficacy and safety profile” (pr.pioneerpublishers.com)) has not gone unnoticed. A shareholder rights law firm (Hagens Berman) announced it is investigating whether Corcept misled investors about relacorilant’s prospects (pr.pioneerpublishers.com). While such lawsuits are fairly common after biotech setbacks, they pose a risk of distraction, legal cost, and in the worst case, financial penalties or settlements. Additionally, Corcept is involved in ongoing intellectual property litigation (e.g. appeals against Teva’s generic). Litigation outcomes can be binary and harmful – for example, losing the Korlym patent suit triggered a stock drop (apnews.com). The reputation of Corcept’s management is also at stake. The FDA episode may have shaken investor trust in management’s transparency or judgment. If confidence in leadership erodes, the stock may suffer a credibility discount or even invite activist investor involvement.

5. Coverage and Reimbursement Risks: As a specialty pharma product, Korlym’s success depends on insurance coverage and reimbursement stability. Corcept relies on a limited number of specialty pharmacy distributors and payers; in fact, a single pharmacy partner (Optime Care) handles a large portion of Korlym prescriptions, and insurers representing ~99% of the company’s revenue have agreements in place for coverage (www.sec.gov). Changes in payer policy – for instance, if insurers decide to favor generics or impose tighter prior authorizations – could hurt sales. Moreover, healthcare legislation like the Inflation Reduction Act introduces drug price negotiation and rebate provisions that could pressure revenues for companies with expensive medications (www.sec.gov) (www.sec.gov). While Korlym’s orphan-drug status may shield it in the near term, future pricing regulations or Medicare negotiations might limit Corcept’s pricing flexibility, thus impacting margins and revenue growth. The company also supports patient assistance programs (charitable foundations for copays); any regulatory scrutiny of such programs could indirectly affect demand. In summary, market access and pricing dynamics present ongoing risk to Corcept’s cash flows.

Red Flags & Areas of Concern

Beyond the broader risks above, a few red flags have emerged in Corcept’s story that investors should monitor closely:

- Management Credibility and Communication: The relacorilant CRL debacle raises questions about management’s communication. The FDA explicitly warned Corcept in advance about inadequacies in its trial data (www.fiercebiotech.com) (wsau.com) – even using unusually strong language to discourage filing – yet management proceeded to submit the NDA and maintained in public that they were confident in approval. After the CRL, the CEO stated surprise at the outcome (www.biospace.com), which in context appears disingenuous. This disconnect between regulatory feedback and public optimism is a red flag for governance. Investors will need to gauge whether this was an isolated overestimation or indicative of a larger transparency issue. It also calls into question the quality of regulatory strategy and advice (Corcept management claims they relied on their regulatory advisors despite FDA’s stance (wsau.com)). Moving forward, management’s credibility with both the FDA and investors may be impaired – a concerning sign if difficult decisions or capital raises arise.

- Drug Efficacy Concerns in Trials: There are red flags in the clinical data. The FDA letter revealed that relacorilant’s pivotal trial results were much weaker than portrayed – “virtually no difference between the drug and placebo” in outcomes (wsau.com) – which casts doubt on Corcept’s prior claims that trial patients “exhibited clinically meaningful improvements” (pr.pioneerpublishers.com). Such a stark contrast suggests that either Corcept’s interpretation of the data was overly rosy or the trial was inadequately designed to capture true benefit. Likewise, the GRADIENT study missed its primary endpoint (pharmaphorum.com). These efficacy red flags indicate a risk that relacorilant may not be effective enough for approval without additional trials. It also raises concern about pipeline quality control – are other trials (e.g., in oncology) being run with robust endpoints? Investors should scrutinize upcoming data readouts (like the ovarian cancer trial ROSELLA) for any signs of overpromising.

- Safety Signals: The liver toxicity signal seen with relacorilant is a safety red flag (wsau.com). While Korlym itself is generally safe (aside from its known side effects related to cortisol blockade and pregnancy termination), relacorilant’s cases of drug-induced liver injury could complicate its risk/benefit calculus. Any severe adverse events in the pipeline programs would similarly be red flags that could halt development. Safety issues not only endanger trial success but can tarnish a company’s reputation with regulators.

- Patent Cliff and Revenue Concentration: As noted, Korlym’s patent protections have largely lapsed, and the drug’s ~$0.5+ billion annual revenue is at risk. Corcept’s own 10-K warns that success is contingent on protecting Korlym’s use patents and fending off generics (www.sec.gov) (www.sec.gov) – a battle that is not going in Corcept’s favor. The loss of exclusivity is a predictable cliff that the company has tried to bridge with relacorilant. Now that relacorilant is delayed, Corcept faces a potential gap where revenues could fall before a new product picks up slack. This vulnerability – a lack of diversified revenue streams – is a fundamental business red flag. By 2026, if generics significantly cannibalize Korlym sales and relacorilant (in any indication) isn’t approved, Corcept could quickly shift from growth to decline.

- Aggressive Growth Targets: Management’s projection of growing the “hypercortisolism business from $3 billion to $5 billion in annual revenues in 3–5 years” (pr.pioneerpublishers.com) appears highly ambitious, considering current revenues are under $1 billion. This kind of bold forecast (implying ~10× revenue expansion) might strike some as unrealistic, especially in light of recent events. The presence of such exuberant targets can be a red flag if not grounded in clear, achievable strategy – it may indicate over-optimism or serve to placate investors. Now that one avenue of growth (Cushing’s expansion via relacorilant) is uncertain, these prior targets seem even farther out of reach.

- Shareholder Dilution or Capital Allocation Missteps: While not an issue yet, investors should watch how Corcept allocates its substantial cash reserve. The 2023 share tender returned value to shareholders, but if the company finds itself needing cash (e.g., to run new trials or in a worst-case Korlym revenue drop), that buyback might in hindsight appear poorly timed. A red flag would be if Corcept has to dilute shareholders with equity raises in the future because cash was expended on buybacks or other uses. Thus far, Corcept’s capital deployment has been shareholder-friendly, but future allocation missteps could hurt investor confidence.

Open Questions & Uncertainties

Looking ahead, there are several open questions that will determine Corcept’s trajectory and whether the recent plunge is a temporary setback or a sign of deeper issues:

- Can Relacorilant Be Salvaged for Cushing’s? Corcept now has to decide how to address the FDA’s demand for more evidence of efficacy. Will the company conduct another clinical trial in Cushing’s syndrome to definitively prove relacorilant’s benefit (e.g. a new Phase 3 focused on key outcomes)? Such a trial could take years and significant investment. Alternatively, can Corcept find a way to slice the existing data or a subset of patients to satisfy the FDA? The CRL gave Corcept one year to resubmit with additional information (wsau.com) – a tight timeline for new data. Investors are waiting for management’s plan: will they appeal or abandon the current NDA and design new studies? The path forward remains unclear. This open question will heavily influence Corcept’s R&D spending and timeline for relacorilant (and thus the growth narrative).

- What Will Happen with the Ovarian Cancer NDA? Apart from Cushing’s, relacorilant is also under FDA review for platinum-resistant ovarian cancer, with a decision (PDUFA) expected by mid-2026 (www.biospace.com). This is based on the phase 3 ROSELLA trial. Does the Cushing’s syndrome CRL foreshadow issues for the oncology indication as well? The mechanisms differ (relacorilant would be used with chemotherapy in cancer), and efficacy there will be judged separately. However, any safety concerns (like liver toxicity) could carry over. An open question is whether FDA’s skepticism extends to relacorilant’s cancer application or if that could still win approval. A related question: if relacorilant does get approved for ovarian cancer, can that indication generate meaningful revenue (given it’s an orphan population and would compete in a crowded oncology space)? The outcome of this NDA could either soften the blow of the Cushing’s failure or compound the disappointment.

- How Will Korlym Hold Up Against Generics? The timing of generic mifepristone market entry is uncertain. Teva might launch at-risk if Corcept’s appeals linger, or there could even be a settlement. Will Corcept’s Korlym sales start declining in 2026? Thus far, the company’s revenue has defied the typical post-patent drop – 2024 sales grew strongly despite Teva’s theoretical ability to launch (www.sec.gov). It’s an open question how long this can last. Perhaps Teva has held off due to the legal overhang or limited patient switching (since Korlym is an orphan drug with a controlled distribution). But eventually, payers may force a switch to generics to cut costs. The trajectory of Korlym in 2026–2027 (steady growth, plateau, or sharp decline) is a critical unknown for forecasting Corcept’s finances. Management’s actions will be telling – e.g., will Corcept consider price adjustments, new formulations, or licensing deals to defend its Cushing’s franchise?

- Can Corcept Diversify Its Pipeline or Portfolio? After this setback, Corcept might seek to diversify beyond relacorilant and cortisol modulation. The company has other earlier-stage cortisol modulators (miricorilant, etc.), but all are internally developed around the same scientific theme. An open question is whether Corcept will use its cash (over $600M) to in-license or acquire other assets to broaden its portfolio. Acquisitions could reduce reliance on the Korlym-relacorilant axis, but finding synergistic opportunities is a challenge. Investors will be watching for any strategic moves or partnerships. The outcome of the ALS (dazucorilant) and NASH (miricorilant) programs is also uncertain – positive data there could open new avenues, while failures would concentrate risk back onto relacorilant’s fate.

- Is Guidance Achievable Post-CRL? Corcept had issued bullish guidance for 2025 ($900–$950M revenue) (ir.corcept.com) and beyond (multi-year growth to multi-billions) (pr.pioneerpublishers.com). Now investors are questioning if those targets are realistic. Will management revise its guidance in light of relacorilant’s delay? The open question is how the company plans to hit near-term growth goals without the Cushing’s expansion from relacorilant. Perhaps Korlym alone, if it continues to be more widely diagnosed/used, could approach $900M for a time – but that assumes no generic erosion and maximum penetration of the patient population. Clarity on guidance will likely come with upcoming earnings calls. Until then, there is uncertainty whether the company can still achieve substantial growth or if a plateau is looming.

- What Changes in Strategy or Management Might Occur? The final open question revolves around how the company will adapt. Will there be management changes or additions to strengthen regulatory affairs after this misstep? Will Corcept’s board become more conservative in pipeline projections, or possibly consider an external review of the relacorilant program? The company’s next steps – whether doubling down on cortisol modulation or pivoting strategy – remain to be seen. Investors may even speculate whether Corcept could become a takeover target for a larger pharma interested in Korlym’s cash flows or the oncology potential of relacorilant. Such strategic questions hang in the air as Corcept works to regain its footing.

In conclusion, Corcept Therapeutics finds itself at a crossroads. The FDA’s warning and relacorilant’s rejection have dealt a blow to the company’s growth narrative and cast uncertainty over its future plans. However, Corcept still has substantial financial strength (profitable operations and cash reserves) and a foothold in the endocrinology market with Korlym – assets that many small biotechs lack. The coming quarters will be pivotal as the company addresses FDA’s concerns, contends with generic competition, and strives to rebuild credibility. Investors should closely watch for updates on relacorilant’s path forward, Korlym’s sales trend amid competition, and any strategic shifts by management. The volatility in CORT shares reflects both the risks and the potential rewards: if Corcept navigates these challenges successfully, there could be significant upside, but missteps or adverse developments could just as easily erode the company’s hard-won progress. All told, Corcept’s story is a reminder of the knife-edge on which biotech companies often balance – where regulatory outcomes and strategic decisions can swiftly swing a stock from surprise triumph to sudden plunge, and vice versa. The next chapters for Corcept will determine which way the scale tips.

Sources: Official company filings and press releases, U.S. FDA communications, and reputable financial news reporting were used in this analysis. Key references include Corcept’s 10-K report (www.sec.gov) (www.sec.gov), investor statements (www.biospace.com) (ir.corcept.com), and news from Reuters and Fierce Biotech detailing the FDA’s warning and stock reaction (wsau.com) (www.fiercebiotech.com). These and other cited sources provide the factual basis for the discussion above, ensuring a grounded and accurate assessment of Corcept Therapeutics’ situation.